Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $568.7 million.

  • Adma Biologics' Liabilities and Shareholders Equity rose 4558.65% to $568.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 4693.89%. This contributed to the annual value of $488.7 million for FY2024, which is 4845.22% up from last year.
  • As of Q3 2025, Adma Biologics' Liabilities and Shareholders Equity stood at $568.7 million, which was up 4558.65% from $558.4 million recorded in Q2 2025.
  • Adma Biologics' Liabilities and Shareholders Equity's 5-year high stood at $568.7 million during Q3 2025, with a 5-year trough of $232.8 million in Q2 2021.
  • In the last 5 years, Adma Biologics' Liabilities and Shareholders Equity had a median value of $343.0 million in 2023 and averaged $360.2 million.
  • As far as peak fluctuations go, Adma Biologics' Liabilities and Shareholders Equity plummeted by 553.26% in 2023, and later skyrocketed by 4845.22% in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' Liabilities and Shareholders Equity stood at $276.3 million in 2021, then increased by 26.14% to $348.5 million in 2022, then fell by 5.53% to $329.2 million in 2023, then soared by 48.45% to $488.7 million in 2024, then rose by 16.37% to $568.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $568.7 million for Q3 2025, versus $558.4 million for Q2 2025 and $510.6 million for Q1 2025.